RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides

Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides With Positive ANCA After Relapse or Resistant Immunosuppressant Therapies

The purpose of this study is to compare a 2 immunosuppressant regimen for the treatment of relapsing or refractory necrotizing antineutrophil cytoplasmic antibody (ANCA) associated vasculitides.

The aim of this study is to compare the efficacy of rituximab versus infliximab in relapsing or refractory forms of ANCA+ vasculitides (Microscopic Polyangiitis, Wegener's granulomatosis and Churg-Strauss syndrome).

Inclusion Criteria:

• Systemic ANCA positive (+) vasculitides
• Relapsing or refractory vasculitides, resistant to corticosteroids and reference immunosuppressant therapies
• Age >18 years old
• Written informed consent

Exclusion Criteria:

• Newly diagnosed patient
• Patient that had never received an immunosuppressant before to treat his/her vasculitis
• Malignancy
• Pregnancy